Sales and Marketing

Showing 15 posts of 11527 posts found.

Bayer cleared of Xarelto ‘breaches’

January 17, 2013 Medical Communications, Sales and Marketing Bayer, PMCPA, Xarelto

Bayer has been found not guilty of making multiple breaches of the ABPI Code of Practice following an anonymous complaint …

Scotland fund for rare diseases

January 17, 2013 Sales and Marketing SMC, Scotland, rare diseases

The Scottish government is launching a £21 million fund in March to meet the costs of patients who require orphan …

MSI appoints senior consultant

January 17, 2013 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing David Watson, MSI Consultancy

Strategic pharma marketing consultancy firm The MSI Consultancy has appointed David Watson as a senior consultant, specialising in channel strategy. …

The price of innovation

January 16, 2013 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, NHS, NICE, Rose, VBP

One of the strange paradoxes of our industry is that we have a very large number of new medicines in …

AstraZeneca shakes up management

January 16, 2013 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Mackay, R&D, Soriot

AstraZeneca has taken its most dramatic steps yet to arrest decline, with chief executive Pascal Soriot axeing two senior positions …

Sanofi Pasteur MSD appoint president of Vaccines Europe

January 16, 2013 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andrea Rappagliosi, Sanofi pasteur msd, vaccines

Vice president of Market Access, Health Policy & Medical Affairs at Sanofi Pasteur MSD Andrea Rappagliosi has been appointed president …

Boehringer in oncology tie-up

January 16, 2013 Research and Development, Sales and Marketing Boehringer, Cancer, horizon, x-man

Boehringer Ingelheim has entered a five-year tie-up with a UK biotech company which specialises in helping research into personalised medicines. …

NICE consults on tamoxifen

January 15, 2013 Sales and Marketing Cancer, Evista, NICE, lilly, tamoxifen

Patient groups have welcomed NICE’s new draft guideline recommending the use of preventive treatments in women who have a family …

Zytiga extended in EU

January 15, 2013 Sales and Marketing EU, J&J, JJ, Janssen, Zytiga

Janssen is celebrating the European Commission’s decision to extend the licence for its prostate cancer treatment Zytiga. The once-daily pill …

Kathryn Gallant joins Insight Health US as joint chief executive

January 14, 2013 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gallant, insight health

The former managing partner for US health at Hall & Partners has joined the consultancy firm Insight Health US as …

Eisai cancer drug fails

January 14, 2013 Research and Development, Sales and Marketing Cancer, Eisai, Morphotek, farletuzumab

Eisai’s investigational oncology treatment farletuzumab has failed to reach its primary endpoint in a late-stage trial. Farletuzumab (MORAb-003) did not …

Merck withdraws Tredaptive

January 14, 2013 Sales and Marketing EMA, Merck, tredaptive

Merck is mounting a global operation to withdraw its cholesterol-lowering drug Tredaptive from the market following safety concerns. The company …

Dominic Atkins joins Clinigen GAP in senior commercial role

January 14, 2013 Manufacturing and Production, Research and Development, Sales and Marketing Clinigen, Dominic Atkins

Pharma services company Clinigen Global Access Programs (Clinigen GAP) has appointed Dominic Atkins as global business development director. In this …

Janssen’s diabetes drug Invokana recommended

January 11, 2013 Sales and Marketing Janssen, SGLT2, canagliflozin, diabetes, invokana

An FDA advisory committee has recommended Janssen’s new diabetes treatment canagliflozin for approval. To be marketed under the name Invokana, …

EU submission for GSK and Theravance COPD drug

January 11, 2013 Sales and Marketing COPD, GSK, Theravance, UMEC/VI

GlaxoSmithKline and Theravance have submitted their chronic obstructive pulmonary disease (COPD) drug UMEC/VI to European regulators. The application follows the …
The Gateway to Local Adoption Series

Latest content